KRAS and colorectal carcinoma: In fact, activating KRAS mutations (occurring in about 30–40% of CRC) are associated with lack of response to EGFR (epidermal growth factor receptor) inhibitors and, at least for panitumumab, have been associated with a detrimental effect with respect to other chemotherapeutic regimens [14].